Science Current Events | Science News | Brightsurf.com
 

FDG-PET Imaging Clearly Predicts Lung Cancer Patients' Response to Chemotherapy

May 10, 2007
Repeating Molecular Imaging Studies Provides Valuable Information for Better Patient Care, Say Researchers in May Journal of Nuclear Medicine

RESTON, Va.—An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients—provided by positron emission tomography (PET) imaging—can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

"Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival," explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. "Although we studied a relatively small number of patients—and our results should be interpreted with caution—it is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile," he said. "The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment," explained Nahmias. "Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach," added the co-author of "Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT."

Non-small cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. -Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with non-small cell lung cancer, current treatments do not cure the cancer.

"With non-small cell lung cancer—since the relatively modest increase in survival must be balanced against the toxicity of the chemotherapeutic treatment—the case for monitoring therapeutic response is especially compelling," said Nahmias. "To assess the response to chemotherapy in patients with advanced non-small cell lung cancer, all of the studies published thus far have evaluated the patients at one, or at most two, time points after the initiation of chemotherapy," said Nahmias. "In our study, we evaluated 15 patients weekly—for seven weeks—as they started their chemotherapy regiment. In spite of the persuasive findings of several studies investigating PET for monitoring response to cancer therapy, until now no published reports have clearly demonstrated that PET results were used to alter treatment," he noted.

PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the body's chemistry, metabolic activity and body function.

"Our result—that PET studies one and three weeks after initiation of cancer therapy can predict success or failure of the therapy—should be validated in a larger study in which patients are enrolled with the intention of applying it in patient management," said Nahmias. He added, "I am forever grateful to all the patients who came back week after week to undergo our PET scans."

"Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT" appears in the May issue of the Journal of Nuclear Medicine, which is published by SNM, the world's largest molecular imaging and nuclear medicine society. Other co-authors are Wahid T. Hanna, Misty J. Long, Karl F. Hubner and David W. Townsend, departments of Medicine and Radiology, University of Tennessee, Knoxville, and Lindi M. Wahl, Department of Applied Mathematics, University of Western Ontario, London, Canada.

Society of Nuclear Medicine


Related Lung Cancer Current Events and Lung Cancer News Articles


Silica dust in small-scale gold mining linked to silicosis and TB epidemic
Silica dust hazards in large gold mines have been well documented, but the situation is far worse in small-scale gold mining according to a new study.

New method enables drug target validation for COPD treatment
Together with clinical partners, a team led by Dr. Dr. Melanie Königshoff and the doctoral student Franziska Uhl at the Comprehensive Pneumology Center of Helmholtz Zentrum München have investigated, for the first time, the suitability of Wnt/beta-catenin.

Pneumonectomy or lobectomy?
For patients in the early stage of non-small cell lung cancer, surgical resection yields optimal outcomes. Prior investigations have shown that different resection procedures have very different outcomes, with pneumonectomy associated with three-fold higher mortality than other resection types.

Simple, active intervention program after major thoracic surgery reduces ER visits and saves money
Hospital readmission rates after major thoracic surgery can run as high as 10-17%. Alarmingly, readmission after pulmonary resection for lung cancer has been associated with worse outcomes, including higher mortality.

New studies examine the significant risk of blood clots in post-surgical lung cancer patients
One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called pulmonary embolism - PE) or in the legs (also known as deep vein thrombosis - DVT).

University of Louisville researchers detail role of silica and lung cancer
Researchers at the University of Louisville have detailed a critical connection associated with a major environmental cause of silicosis and a form of lung cancer.

AGS unveils revised Choosing Wisely list of topics to talk about with older adults
The American Geriatrics Society (AGS) today released updates to several of its recommendations for the ABIM Foundation's Choosing Wisely® campaign, which raises professional and public awareness about treatments and tests to question and discuss because they may lack efficacy or cause potential harm.

Proton radiotherapy delivers more accurate cancer treatment, with less collateral damage
Radiotherapy using protons can deliver more accurate treatment to a tumour while reducing the dose to surrounding tissue.

Health insurance coverage among cancer patients varies greatly by demographics and cancer type
A new analysis has found that, among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type.

Mayo Clinic researchers identify methylated DNA markers -- noninvasive cancer screen
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors.
More Lung Cancer Current Events and Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)


The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and...

Lung Cancer: Diagnosis and Management

Lung Cancer: Diagnosis and Management
by CME Resource/NetCE


The purpose of this course is to address the various aspects of diagnosis, treatment, disease management and appropriate patient care for healthcare professionals caring for patients with lung cancer. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.

Upon completion of this course, you should be able to:
1. Discuss the risk factors and incidence of lung cancer.
2. Explain the pathophysiology of lung cancer.
3. Identify the signs and symptoms of lung cancer.
4. Discuss the various tests used to diagnose lung cancer.
5. Describe the lung cancer classification and staging system.
6. Discuss the treatment options available to the patient with lung cancer, including potential...

How to Survive Lung Cancer - A Practical 12-Step Plan

How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)


Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)


Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions. This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of...

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope
by Bonnie J. Addario (Author), MD, PhD, Shane P. Dormady (Author), RN, MSN, CPHQ, Eileen Johnson (Author), RN, MBA, Alicia Sable-Hunt (Author), Danielle Hicks (Editor), MD, Paul Hesketh (Editor), MD, Robert Sinha (Editor), MD, PhD, D. Ross Camidge (Editor), MD, Elizabeth A. David (Editor), MD, Lisa Boohar (Editor), MD, David R. Gandara (Editor), PhD, Guneet Walia (Editor), Inc., Sheila Von Driska?White Space (Editor)


Navigating Lung Cancer 360 Degrees of Hope is the most comprehensive guidebook for surviving lung cancer. Inside each latest edition you will get the most up-to-date navigation tools on the diagnosis process, lung cancer staging, treatment options, clinical trials, living with lung cancer, financing your care, hope for surviving lung cancer, and more. Written by survivor Bonnie J. Addario and the leading experts in lung cancer with one goal: to turn lung cancer into a manageable and survival disease.

Johns Hopkins Patients' Guide To Lung Cancer

Johns Hopkins Patients' Guide To Lung Cancer
by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author)


Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow “how to” guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

Understanding Lung Cancer: An Introduction for Patients and Caregivers

Understanding Lung Cancer: An Introduction for Patients and Caregivers
by Naheed Ali (Author)


Cancer of any kind is scary, but lung cancer is unique in that most people think that only people who smoke can or do get it. The truth is that anyone can get lung cancer, and it can be deadly. In 2008 (the most recent year numbers are available), 208,493 people in the United States were diagnosed with lung cancer, while 158,592 people in the United States died from lung cancer. Here, Dr. Naheed Ali dispels the notion that only smokers develop lung cancer, but also goes over their increased risk for getting the disease, while also considering the risk factors that non-smokers face. He provides background and tips for combating lung cancer, from prevention, to treatment, to coping with the disease should a person fall victim.

In typical fashion, Ali helps readers to understand...

Living with Lung Cancer--My Journey

Living with Lung Cancer--My Journey
by Thomas E. Cappiello (Author)


On October 5 2007, Thomas Cappiello was diagnosed with inoperable Stage IIIA locally-advanced adenocarcinoma (Non-Small Cell Lung Cancer), an incurable disease. This book is the inspirational story of how he beat the odds and survived and thrived in the face of this devastating illness. This book is for patients and caregivers who want to know what life is like after getting a cancer diagnosis. The story is about overcoming the emotional turmoil and devastation of a cancer diagnosis, dealing with the disease, and making choices. Most of all, it's about living a full life each day. Cancer patients suddenly realize that time is a precious gift from God and there is no time to waste. By telling his story Cappiello seeks to inspire cancer patients to fight hard and live, with whatever time...

Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)

Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)
by Harvey I. Pass MD (Editor), David P. Carbone MD PhD (Editor), David H. Johnson MD (Editor), John D. Minna MD (Editor), Giorgio V. Scagliotti MD (Editor), Andrew T. Turrisi III MD (Editor)


Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques. This edition has expanded thoracic oncology chapters including thymus, mesothelioma, and mediastinal tumors, more detailed discussion of targeted agents, and state-of-the-art information on newer techniques in radiotherapy. Other highlights include more international...

© 2015 BrightSurf.com